| Bioactivity | NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentiates CDDP efficacy in cancer[1]. | ||||||||||||
| Target | IC50: 0.42 μM (ERCC1-XPF). | ||||||||||||
| Invitro | NSC16168 (0-50 μM) potentiates cisplatin efficacy in cancer cells[1]. Cell Viability Assay[1]. Cell Line: | ||||||||||||
| In Vivo | NSC16168 (20 mg/kg, ip, twice daily) exhibits significant anti-tumor activity and potentiates cisplatin antitumor activity in H460 lung cancer xenografts[1]. Animal Model: | ||||||||||||
| Name | NSC16168 | ||||||||||||
| CAS | 6837-93-0 | ||||||||||||
| Formula | C17H15NO9S3 | ||||||||||||
| Molar Mass | 473.50 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Arora S, et al. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells. Oncotarget. 2016 Nov 15;7(46):75104-75117. |
NSC16168
CAS: 6837-93-0 F: C17H15NO9S3 W: 473.50
NSC16168 is a specific inhibitor of ERCC1-XPF, with an IC50 value of 0.42 μM. NSC16168 inhibits DNA repair and potentia
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.